Envestnet Asset Management Inc. Has $13.25 Million Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

Envestnet Asset Management Inc. trimmed its position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 9.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 891,183 shares of the company's stock after selling 93,495 shares during the period. Envestnet Asset Management Inc.'s holdings in Takeda Pharmaceutical were worth $13,252,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. FNY Investment Advisers LLC bought a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at $37,000. Farther Finance Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after acquiring an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at $52,000. Fifth Third Bancorp lifted its stake in shares of Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after acquiring an additional 2,411 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after acquiring an additional 1,296 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $14.42 on Friday. The firm has a market cap of $45.88 billion, a PE ratio of 65.55 and a beta of 0.23. The firm's fifty day moving average is $14.83 and its 200-day moving average is $14.43. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. Sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.